Stanford Cancer Institute
Gastrointestinal

Colorectal

Metastatic

2nd Line

GI0022
Phase II/III Global Multicenter Open-Label Umbrella Study Evaluating Safety & Efficacy of Targeted Therapies in Subpopulations of Patients w/ Metastatic Colorectal Cancer (INTRINSIC)

PI: Fisher
Sponsor: F. Hoffmann-La Roche Ltd

COR0023
Phase II Randomized Open Label Study Evaluating the Safety & Efficacy of Magrolimab in Combination w/ Bevacizumab & FOLFIRI vs Bevacizumab & FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (CRC)

PI: Fisher
Sponsor: Gilead Sciences, Inc.

GI0025
Phase I Study to Evaluate Safety, Pharmacokinetics & Preliminary Antitumor Activity of PEEL-224 in Advanced Solid Tumors

PI: Fisher
Sponsor: PEEL Therapeutics, Inc.

COR0026
Phase I/II First-in-Human Study of BMS-986288 Alone & in Combination w/ Nivolumab in Advanced Malignant Tumors

PI: Holden
Sponsor: Bristol-Myers Squibb

SARCOMA0058
Phase III Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Oligometastatic Tumors in the Lung

PI: Bedi
Sponsor: NeuWave Therapeutics, Inc. (Part of J&J Medical Devices Division)

VAR0251
Phase I Safety & Efficacy of LYL845 in Adults w/ Relapsed &/or Refractory Metastatic or Locally Advanced Melanoma & Selected Solid Tumor Malignancies

PI: Betof Warner
Sponsor: Lyell Immunopharma Inc.

Locally Advanced

None at this time

GI0030
Phase II/III Open-Label Study to Investigate the Safety Tolerability Pharmacokinetics Pharmacodynamics & Preliminary Antitumor Activity of AT-1965 in Advanced Refractory or Recurrent Solid Tumors

PI: Goyal
Sponsor: Alyssum Therapeutics Inc.

KEY

<table>
<thead>
<tr>
<th>Status</th>
<th>Icon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pending</td>
<td></td>
</tr>
<tr>
<td>Open for Enrollment</td>
<td>Link</td>
</tr>
<tr>
<td>Closed</td>
<td>Optional Path</td>
</tr>
<tr>
<td>Trial Posting</td>
<td>Extension Study</td>
</tr>
<tr>
<td>Enrollment on Hold</td>
<td>Immunotherapy</td>
</tr>
</tbody>
</table>

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu